Eli Lilly | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Abbott USD 13B 1.15B 2025-03
ALKERMES USD 443.73M 21.47M 2025-03
Amgen USD 23.01B 91M 2025-03
AstraZeneca USD 29.13B 1.26B 2025-03
Baxter International USD 6.51B 311M 2024-12
Biogen USD 5.3B 231.4M 2025-03
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Drreddys Laboratories INR 131.95B 2.65B 2024-12
Eli Lilly USD 30.07B 1.69B 2025-03
Gilead Sciences USD 12B 279M 2024-12
GlaxoSmithKline GBP 20.83B 866M 2025-03
Glaxosmithkline GBP 21.7B 238M 2024-12
Indivior 1.01B 66M 2025-03
J&J USD 56.9B 6.58B 2025-03
Medtronic USD 11.84B 355M 2025-01
Merck USD 25.17B 3.25B 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Novartis USD 28.69B 560M 2024-12
Novo Nordisk 236.12B 27.76B 2025-03
Perrigo USD 1.07B 29.6M 2025-03
Pfizer USD 36.45B 6.54B 2025-03
Prestige Brands USD 102.54M 4.36M 2024-12
Regeneron Pharmaceuticals USD 3.57B 2.13B 2025-03
Roche Holding CHF 27.02B 424M 2024-12
Sanofi 32.22B 3.06B 2025-03
Sanofi 29.16B 865M 2024-12
United Therapeutics USD 721.5M 16.6M 2025-03
Zoetis USD 3.38B 27M 2025-03



Eli Lilly Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.